Target intelligence / Profile preview

Methyl-CpG-binding domain protein 3-like 2B (MBD3L2B)

Target
MBD3L2B
Molecular classification
Other (putative chromatin regulator, not a classical receptor, enzyme, transporter, or ion channel)
01

Overview

Methyl-CpG-binding domain protein 3-like 2B (MBD3L2B) is a predicted protein in humans encoded by the MBD3L2B gene, a paralog of MBD3L2[1][7]. It is believed to play a role in chromatin regulation, specifically in heterochromatin formation linked to DNA methylation, and may negatively regulate transcription by RNA polymerase II[1]. The protein is predicted to have methyl-CpG binding activity, binds to nuclear chromatin, and is predicted to be localized in the nucleus. However, direct evidence for this protein’s function is lacking, and it is not considered a validated therapeutic target (i.e., not a classical receptor, enzyme, or transporter). MBD3L2B belongs to a family of MBD3L proteins whose genetic locus (19p13) has multiple copies, with uncertain numbers of functional genes, and its specific biological or pathological role remains unclear[7]. Additional context and limitations: - There is no evidence that MBD3L2B is a validated drug target, and it is not associated with any known drug interactions or specific disease roles[1][7][10]. - The MBD3L2 gene (a related family member) has been found in germ cell tumors and some somatic tissues, but this is not documented for MBD3L2B[5]. - The gene's predicted function is inferred from homology to other MBD (methyl-CpG binding domain) family proteins. - MBD3L2B is sometimes confused with closely related family members MBD3L2 or MBD3, which have better characterized roles in chromatin regulation and interaction with NuRD complexes[2][5], but current evidence does not support this for MBD3L2B itself. - No structured information is available regarding drugs, biomarkers, mechanisms of action, or safety concerns for therapeutic targeting. Summary: MBD3L2B is a human protein of unknown or poorly characterized biological and clinical relevance. It is not considered a drug target or established receptor, enzyme, or similar molecule. Its entry as a "target" should be regarded as likely incorrect, based on the current state of scientific evidence[1][7][10].

Other names
MBD3L2Bmethyl-CpG binding domain protein 3 like 2B
02

Biological functions

Predicted methyl-CpG binding activityDNA methylation-dependent constitutive heterochromatin formationNegative regulation of transcription by RNA polymerase II

Beyond the preview

Go deeper on Methyl-CpG-binding domain protein 3-like 2B (MBD3L2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyl-CpG-binding domain protein 3-like 2B (MBD3L2B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call